Sign inJoin waitlistJoin the waitlist

Don Gibbons

Professor, Thoracic/Head and Neck Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2006–2009
Internal Medicine
Baylor College of Medicine
2004–2006
Center
Albert Einstein College of Medicine
2000–2004
Harvard University
1996–2000

Research

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase…
Journal of Clinical Oncology · 2019 · 1,075 citations
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic…
The Lancet Oncology · 2016 · 930 citations
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Nature Communications · 2014 · Co-first of 30 authors · 834 citations

John Heymach
142 papers
Jianjun Zhang
110 papers
Tina Cascone
57 papers · 3 as a fellow
Ara Vaporciyan
55 papers
Lauren Byers
55 papers
Xiuning Le
49 papers
BS
Boris Sepesi
48 papers
JL
Joanna Lee
45 papers · 2 as a resident
Stephen Swisher
42 papers
Natalie Vokes
40 papers
Jonathan Kurie
37 papers
Marcelo Negrao
36 papers

Grants

Targeting Lung Cancer Vulnerabilities
National Cancer Institute · P50
Project lead · $240.6K · Ut Southwestern Medical Center
1997–2026
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
National Cancer Institute · R37
Contact PI · $2.7M · University of Tx Md Anderson Can Ctr
2018–2024
MicroRNA-200 Family Regulation by the Apical-Basal Polarity Complexes in EMT and
National Cancer Institute · K08
Contact PI · $853.2K · University of Tx Md Anderson Can Ctr
2010–2015
Notch and Stem Cells in Lung Cancer Treated with Erlotinib Plus Notch Inhibitor.
National Cancer Institute · R21
Contact PI · $506.9K · University of Tx Md Anderson Can Ctr
2011–2014

Clinical trials

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2019–2025
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2018–2024
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Principal investigator · Completed · Phase 1
MedImmune LLC
2014–2021
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2010–2015